450
Participants
Start Date
July 31, 2022
Primary Completion Date
September 29, 2024
Study Completion Date
September 29, 2024
Combination of Imipenem/Cilastatin and XNW4107
Imipenem/Cilastatin 500mg/500mg and XNW4107 250mg for Injection
Imipenem/Cilastatin/Relebactam
Imipenem/Cilastatin/Relebactam 1.25 g for Injection
VA medical center, Buffalo
University of Maryland Medical Center, Baltimore
Carolinas Medical Center, Charlotte
Chu Nimes, Nîmes
Jackson Memorial Hospital (JMH) - Ryder Trauma Center, Miami
USF-TGH, Tampa
Hartford Hospital, Hartford
The University of Tennessee Medical Center, Knoxville
Hillel Yaffe Medical Center, Hadera
Hospital Universitario de Tarragona Joan XXIII, Tarragona
University Hospitals Cleveland Medical Center, Cleveland
Chu Reims- Medical Icu, Reims
Wolfson Medical Center, H̱olon
Tel Aviv Medical Center, Tel Aviv
Cox Health, Springfield
Hôpitaux Universitaires de Strasbourg, Strasbourg
Nouvel Hopital CIVIL/ Medecine Intensive Reanimation, Strasbourg
Shamir Medical Center, Be’er Ya‘aqov
Cochin, Paris
Groupe Hospitalier Paris Saint-Joseph, Paris
APHP, Paris
intensive Unit Care CHU Amiens Picardie, Amiens
Denver Health and Hospital Authority, Denver
Hôpital Foch, Suresnes
CH victor dupouy, Argenteuil
Galilee Medical Center / Department int med A, Nahariya
Bnei-Zion Medical Center, Haifa
Rambam Critical Care division, Haifa
Sheba Medical Center, Ramat Gan
CHU de Nice, Nice
Hospital del Mar, Barcelona
Hospital Universitari Vall Hebron, Barcelona
Hospital Clínic of Barcelona, Barcelona
Hospital de la Santa Creu i Sant Pau, Barcelona
Bellvitge University Hospital, L'Hospitalet de Llobregat
Lead Sponsor
Evopoint Biosciences Inc.
INDUSTRY